P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY

por Spiliopoulou, V., Ntanasis-Stathopoulos, I., Malandrakis, P., Gavriatopoulou, M., Theodorakakou, F., Fotiou, D., Syrigou, R. E., Migkou, M., Roussou, M., Eleutherakis-Papaiakovou, E., Kastritis, E., Dimopoulos, M. A, Terpos, E.
Publicado 2023

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA

por Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Eleutherakis-Papaiakovou, E., Malandrakis, P., Spiliopoulou, V., Syrigou, R.E., Theodorakakou, F., Fotiou, D., Migkou, M., Roussou, M., Kastritis, E., Dimopoulos, M.A., Terpos, E.
Publicado 2023

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

por Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Malandrakis, P., Fotiou, D., Kanellias, N., Migkou, M., Theodorakakou, F., Spiliopoulou, V., Syrigou, R., Eleutherakis-Papaiakovou, E., Gkolfinopoulos, S., Manousou, K., Kastritis, E., Dimopoulos, M.A., Terpos, E.
Publicado 2023